메뉴 건너뛰기




Volumn 22, Issue 5, 2013, Pages 894-897

HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy

Author keywords

Breast conserving treatment; Ductal carcinoma in situ; Human epidermal growth factor receptor 2; Local recurrence; Radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

EID: 84884128985     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.001     Document Type: Article
Times cited : (11)

References (19)
  • 2
    • 33746811910 scopus 로고    scopus 로고
    • Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group
    • Bijker N., Meijnen P., Peterse J.L., Bogaerts J., Van Hoorebeeck I., Julien J.P., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. JClin Oncol 2006, 24:3381-3387.
    • (2006) JClin Oncol , vol.24 , pp. 3381-3387
    • Bijker, N.1    Meijnen, P.2    Peterse, J.L.3    Bogaerts, J.4    Van Hoorebeeck, I.5    Julien, J.P.6
  • 3
    • 0034883290 scopus 로고    scopus 로고
    • Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and bowel project experience
    • Fisher B., Land S., Mamounas E., Dignam J., Fisher E.R., Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and bowel project experience. Semin Oncol 2001, 28:400-418.
    • (2001) Semin Oncol , vol.28 , pp. 400-418
    • Fisher, B.1    Land, S.2    Mamounas, E.3    Dignam, J.4    Fisher, E.R.5    Wolmark, N.6
  • 4
    • 0031941704 scopus 로고    scopus 로고
    • Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17
    • Fisher B., Dignam J., Wolmark N., Mamounas E., Costantino J., Poller W., et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. JClin Oncol 1998, 16:441-452.
    • (1998) JClin Oncol , vol.16 , pp. 441-452
    • Fisher, B.1    Dignam, J.2    Wolmark, N.3    Mamounas, E.4    Costantino, J.5    Poller, W.6
  • 5
    • 79952845819 scopus 로고    scopus 로고
    • Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
    • Wapnir I.L., Dignam J.J., Fisher B., Mamounas E.P., Anderson S.J., Julian T.B., et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. JNatl Cancer Inst 2011, 103:478-488.
    • (2011) JNatl Cancer Inst , vol.103 , pp. 478-488
    • Wapnir, I.L.1    Dignam, J.J.2    Fisher, B.3    Mamounas, E.P.4    Anderson, S.J.5    Julian, T.B.6
  • 6
    • 79851509160 scopus 로고    scopus 로고
    • Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis
    • Wang S.Y., Shamliyan T., Virnig B.A., Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 2011, 127:1-14.
    • (2011) Breast Cancer Res Treat , vol.127 , pp. 1-14
    • Wang, S.Y.1    Shamliyan, T.2    Virnig, B.A.3    Kane, R.4
  • 10
    • 0242380840 scopus 로고    scopus 로고
    • Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast
    • Provenzano E., Hopper J.L., Giles G.G., Marr G., Venter D.J., Armes J.E. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003, 39:622-630.
    • (2003) Eur J Cancer , vol.39 , pp. 622-630
    • Provenzano, E.1    Hopper, J.L.2    Giles, G.G.3    Marr, G.4    Venter, D.J.5    Armes, J.E.6
  • 12
    • 84858285120 scopus 로고    scopus 로고
    • HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
    • Rakovitch E., Nofech-Mozes S., Hanna W., Narod S., Thiruchelvam D., Saskin R., et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012, 106:1160-1165.
    • (2012) Br J Cancer , vol.106 , pp. 1160-1165
    • Rakovitch, E.1    Nofech-Mozes, S.2    Hanna, W.3    Narod, S.4    Thiruchelvam, D.5    Saskin, R.6
  • 13
    • 84872320423 scopus 로고    scopus 로고
    • Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database
    • Ko B.S., Noh W.C., Kang S.S., Park B.W., Kang E.Y., Paik N.S., et al. Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database. JBreast Cancer 2012, 15:393-400.
    • (2012) JBreast Cancer , vol.15 , pp. 393-400
    • Ko, B.S.1    Noh, W.C.2    Kang, S.S.3    Park, B.W.4    Kang, E.Y.5    Paik, N.S.6
  • 14
    • 33750584030 scopus 로고    scopus 로고
    • HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
    • Wen X.F., Yang G., Mao W., Thornton A., Liu J., Bast R.C., et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006, 25:6986-6996.
    • (2006) Oncogene , vol.25 , pp. 6986-6996
    • Wen, X.F.1    Yang, G.2    Mao, W.3    Thornton, A.4    Liu, J.5    Bast, R.C.6
  • 16
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005, 353:1673-1684.
    • (2005) NEngl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3    Suman, V.J.4    Geyer, C.E.5    Davidson, N.E.6
  • 17
    • 78650711397 scopus 로고    scopus 로고
    • Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
    • Kuerer H.M., Buzdar A.U., Mittendorf E.A., Esteva F.J., Lucci A., Vence L.M., et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011, 117:39-47.
    • (2011) Cancer , vol.117 , pp. 39-47
    • Kuerer, H.M.1    Buzdar, A.U.2    Mittendorf, E.A.3    Esteva, F.J.4    Lucci, A.5    Vence, L.M.6
  • 18
    • 84865182133 scopus 로고    scopus 로고
    • Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
    • von Minckwitz G., Darb-Esfahani S., Loibl S., Huober J., Tesch H., Solbach C., et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2012, 132:863-870.
    • (2012) Breast Cancer Res Treat , vol.132 , pp. 863-870
    • von Minckwitz, G.1    Darb-Esfahani, S.2    Loibl, S.3    Huober, J.4    Tesch, H.5    Solbach, C.6
  • 19
    • 84884135755 scopus 로고    scopus 로고
    • National Cancer Institute. NSABP B-43. A phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive DCIS resected by lumpectomy. Available from: [cited 2012 Aug 30]
    • National Cancer Institute. NSABP B-43. A phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive DCIS resected by lumpectomy. Available from: [cited 2012 Aug 30]. http://www.clinicaltrials.gov/ct2/show/NCT00769379.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.